{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lister A"],"funding":["Cancer Research UK","Medical Research Council","National Institute for Health Research (NIHR)"],"pagination":["37"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3098205"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["<h4>Background</h4>Nrf2 is a key transcriptional regulator of a battery of genes that facilitate phase II/III drug metabolism and defence against oxidative stress. Nrf2 is largely regulated by Keap1, which directs Nrf2 for proteasomal degradation. The Nrf2/Keap1 system is dysregulated in lung, head and neck, and breast cancers and this affects cellular proliferation and response to therapy. Here, we have investigated the integrity of the Nrf2/Keap1 system in pancreatic cancer.<h4>Results</h4>Keap1, Nrf2 and the Nrf2 target genes AKR1c1 and GCLC were detected in a panel of five pancreatic cancer cell lines. Mutation analysis of NRF2 exon 2 and KEAP1 exons 2-6 in these cell lines identified no mutations in NRF2 and only synonomous mutations in KEAP1. RNAi depletion of Nrf2 caused a decrease "],"journal":["Molecular cancer"],"pubmed_title":["Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy."],"pmcid":["PMC3098205"],"funding_grant_id":["G0700654","NF-SI-0510-10126","C6665/A7348"],"pubmed_authors":["Costello E","Neoptolemos JP","Kitteringham NR","Lloyd B","Campbell F","Goldring CE","Owen A","Nedjadi T","Lister A","Copple IM","Williams S","Park BK"],"additional_accession":[]},"is_claimable":false,"name":"Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.","description":"<h4>Background</h4>Nrf2 is a key transcriptional regulator of a battery of genes that facilitate phase II/III drug metabolism and defence against oxidative stress. Nrf2 is largely regulated by Keap1, which directs Nrf2 for proteasomal degradation. The Nrf2/Keap1 system is dysregulated in lung, head and neck, and breast cancers and this affects cellular proliferation and response to therapy. Here, we have investigated the integrity of the Nrf2/Keap1 system in pancreatic cancer.<h4>Results</h4>Keap1, Nrf2 and the Nrf2 target genes AKR1c1 and GCLC were detected in a panel of five pancreatic cancer cell lines. Mutation analysis of NRF2 exon 2 and KEAP1 exons 2-6 in these cell lines identified no mutations in NRF2 and only synonomous mutations in KEAP1. RNAi depletion of Nrf2 caused a decrease ","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Apr","modification":"2026-04-07T15:15:57.011Z","creation":"2019-03-27T00:41:47Z"},"accession":"S-EPMC3098205","cross_references":{"pubmed":["21489257"],"doi":["10.1186/1476-4598-10-37"]}}